Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.175 CAD | -12.50% | -5.41% | -16.67% |
Apr. 08 | Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding | CI |
Mar. 28 | Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 42M 57.75M |
---|---|---|---|---|---|
Net income 2022 | -6M -8.25M | Net income 2023 | -6M -8.25M | EV / Sales 2022 | - |
Net cash position 2022 | 784K 1.08M | Net cash position 2023 | 808K 1.11M | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.33
x | P/E ratio 2023 |
-6.45
x | Employees | 9 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.24% |
1 day | -12.50% | ||
1 week | -5.41% | ||
Current month | -2.78% | ||
1 month | -2.78% | ||
3 months | -18.60% | ||
6 months | -25.53% | ||
Current year | -16.67% |
Managers | Title | Age | Since |
---|---|---|---|
Jacek Antas
CEO | Chief Executive Officer | - | 22-04-17 |
Director of Finance/CFO | 59 | Feb. 13 | |
Chief Tech/Sci/R&D Officer | - | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 22-04-17 | |
Jacek Antas
CEO | Chief Executive Officer | - | 22-04-17 |
Malgorzata Laube
BRD | Director/Board Member | - | 22-12-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 0.175 | -12.50% | 5,056 |
24-04-15 | 0.2 | +8.11% | 1,011 |
24-04-11 | 0.185 | 0.00% | 1,051 |
Delayed Quote Toronto S.E., April 17, 2024 at 02:13 pm EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.67% | 29.2M | |
-1.75% | 41.35B | |
+42.15% | 40.38B | |
+1.45% | 39.05B | |
-14.19% | 26.67B | |
+2.15% | 24.07B | |
-24.46% | 18.36B | |
-4.15% | 11.68B | |
+21.33% | 11.6B | |
+7.81% | 11.15B |
- Stock Market
- Equities
- HBP Stock